NDC Active Ingredient Ado-trastuzumab Emtansine

Immunotoxin that consists of humanized monoclonal anti-HER2 antibody TRASTUZUMAB covalently linked to anti-microtubule agent MAYTANSINOID DM1 for treatment of metastatic breast cancer in patients who previously received trastuzumab and a TAXANES, separately or in combination.

Trastuzumab emtansine is used to treat certain types of breast cancer. This medication is used to treat tumors that produce more than the normal amount of a certain substance called HER2 protein. This medication is called a monoclonal antibody and microtubule inhibitor conjugate. Trastuzumab emtansine works by attaching to the HER2 cancer cells and blocking them from dividing and growing. It may also destroy the cancer cells or signal the body (immune system) to destroy the cancer cells. This monograph is about the following trastuzumab emtansine products: trastuzumab emtansine, ado-trastuzumab emtansine.

The NDC database has 1 products with the active ingredient Ado-trastuzumab Emtansine. The following table lists all the products that have this active ingredient.